From Platform Knowledge to Commercial Readiness: Accelerating and De-risking your AAV Therapy’s Path to Patients

As AAV-based gene therapy programs move from late-stage clinical development toward commercialisation, Chemistry, Manufacturing and Controls (CMC) execution often becomes a key determinant of launch readiness.

This webinar will explore how process characterisation, control strategy development, analytical readiness and Process Performance Qualification (PPQ) planning can come together while remaining scientifically sound, operationally practical and defensible in future regulatory interactions. For rare disease programs in particular, where timelines, material availability and patient need are especially constrained, avoiding late-stage CMC surprises is important.

By leveraging prior process understanding, established analytical capabilities and structured CMC data, developers may be able to reduce duplicated effort, streamline process characterisation and PPQ planning and improve predictability as programs approach BLA readiness. External benchmarking of AAV commercialisation pathways has shown that CMC-related delays can materially affect time to approval, underscoring the value of early, risk-based planning and platform-informed execution.

Attendees will learn how MSAT teams can help bridge development, manufacturing, analytics and regulatory strategy, turning process knowledge into actionable decisions that support PPQ readiness and efficient commercialisation of AAV gene therapies.
The featured speaker will discuss how a manufacturing platform with a fit-for-purpose MSAT strategy can support the transition from clinical manufacturing to commercial readiness for AAV products. The session will focus on the pre-PPQ activities that help establish a robust control strategy, including critical quality attribute definition, process parameter and performance attribute assessment, risk-based process FMEA, scale-down model qualification and process characterisation study design. A client case study will illustrate key commercialisation-enabling activities for an AAV program while protecting product-specific information.

The discussion will also highlight the decision-making framework behind these activities, with illustrative examples of how process characterisation outputs can inform safe operating ranges, set-points and control strategy decisions.
Register for this webinar to learn how platform knowledge, process characterisation and PPQ planning can help accelerate and de-risk AAV therapy commercialisation.

Who Should Attend
This webinar will appeal to:

• Therapeutic developers using AAV in the manufacture of cell and gene therapies
• CMC professionals
• MSAT scientists and leaders
• Process Development Scientists
• Manufacturing Scientists and Engineers

What You Will Learn
Attendees will gain insight into:

• How platform knowledge can reduce duplicated effort and support more efficient AAV commercialisation
• How MSAT teams can connect development, manufacturing, analytics and regulatory strategy as programs approach PPQ
• The pre-PPQ activities required to establish a robust control strategy, including critical quality attributes, process parameters, FMEA and scale-down model qualification
• How process characterisation data can inform safe operating ranges, set-points and control strategy decisions

Register free on Xtalks:
https://xtalks.com/webinars/from-platform-knowledge-to-commercial-readiness-accelerating-and-de-risking-your-aav-therapys-path-to-patients/